gamma-aminobutyric acid has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 3 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Whether GABA may be involved with acute lymphoblastic leukemia (ALL) is unclear." | 1.43 | Up-Regulation of GABAergic Signal Events in Bone Marrow Lymphocytes in Childhood Acute Lymphoblastic Leukemia. ( Cui, S; Feng, M; Li, T; Liu, C; Liu, Y; Qian, M; Wang, H; Wang, S; Wei, C; Yang, X; Yi, F, 2016) |
| "Improved cure rates for childhood acute lymphoblastic leukemia (ALL) over the past 2 decades have allowed greater attention to patients' quality of life." | 1.37 | Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. ( Anghelescu, DL; Cheng, C; Faughnan, LG; Hankins, G; Hinds, PS; Jeha, S; Pauley, JL; Pei, D; Pui, CH; Relling, MV; Sandlund, JT, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 1 |
| Feng, M | 1 |
| Liu, Y | 1 |
| Wei, C | 1 |
| Qian, M | 1 |
| Li, T | 1 |
| Yang, X | 1 |
| Cui, S | 1 |
| Liu, C | 1 |
| Yi, F | 1 |
| Wang, S | 1 |
| Anghelescu, DL | 1 |
| Faughnan, LG | 1 |
| Jeha, S | 1 |
| Relling, MV | 1 |
| Hinds, PS | 1 |
| Sandlund, JT | 1 |
| Cheng, C | 1 |
| Pei, D | 1 |
| Hankins, G | 1 |
| Pauley, JL | 1 |
| Pui, CH | 1 |
| Masuda, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
1 review available for gamma-aminobutyric acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
[The molecular mechanism of Notch-induced transformation and the therapeutic potential of its inhibitor].
Topics: Alanine; Amyloid Precursor Protein Secretases; Azepines; Cytoplasm; gamma-Aminobutyric Acid; Humans; | 2006 |
2 other studies available for gamma-aminobutyric acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Up-Regulation of GABAergic Signal Events in Bone Marrow Lymphocytes in Childhood Acute Lymphoblastic Leukemia.
Topics: Blotting, Western; Bone Marrow Cells; Case-Control Studies; Child; Child, Preschool; Female; gamma-A | 2016 |
Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Child; Child, Preschool; | 2011 |